TAIPEI, Taiwan – Artificial intelligence is already changing health care, but the revolution is only just beginning, and within the coming decade it will have completely transformed the biotech industry as we know it.
TAIPEI, Taiwan – One of the more interesting questions in biopharma today is the direction in which the biosimilars market is headed. Speaking at the BioBusiness Asia Conference, part of BioTaiwan 2017, industry insiders shared their views on the outlook for this market, highlighting the state of flux and uncertainty that still defines the segment.
TAIPEI, Taiwan – Taiwan's biopharma industry faces strong competition from both China and South Korea, but its geographic position on the edge of Southeast Asia provides an advantage in marketing a potential dengue vaccine to the young and fast-growing region.
TAIPEI, Taiwan – Aslan Pharmaceuticals Pte. Ltd., a Singapore-based company focused on the development of treatments for prevalent tumor types in Asia, is conducting a competitive auction and public offer of common shares for its initial listing on the Taipei Exchange (TPEx).
TAIPEI, Taiwan – Aslan Pharmaceuticals Pte. Ltd., a Singapore-based company focused on the development of treatments for prevalent tumor types in Asia, is conducting a competitive auction and public offer of common shares for its initial listing on the Taipei Exchange (TPEx).
TAIPEI, Taiwan – The global biotech market is in a period of low productivity, high costs and less-than-ideal levels of efficiency. Such conditions are pushing pharmaceutical firms in the Asia-Pacific region to develop creative strategies that often require looking elsewhere for innovative solutions and products.
TAIPEI, Taiwan – During the two days of talks, roundtables and panel discussions at the recent Biologics World Taiwan 2017, much of the attention speakers devoted to Taiwan focused on what the country is not getting right, from government support and policies, to competing with regional rivals.
TAIPEI, Taiwan – The government here, despite its good intentions, needs to make changes in its approach to the biopharma industry quickly, said speakers during the Biologics World Taiwan 2017 conference.
